Presenting at a significant industry summit can often lead to increased visibility and investor interest, especially in the biotech sector where innovation is key. Molecular Partners' focus on DARPin oncology innovations could be seen as a positive development, suggesting progress in their proprietary technology and potential future growth. This could lead to a short-term positive impact on the stock price.